Loading...
1 / 2
IGF-1LR3
Add to Wishlist
Long-Acting Insulin-Like Growth Factor for Muscle Hyperplasia
In Stock
Select Size
$60.00$72.00
You Save
$12.00In Stock — Ships Same Day
Includes
0.1mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
IGF-1 LR3 (Long Arginine 3-IGF-1) is a synthetic 83-amino acid analog of insulin-like growth factor-1 that has been modified with an arginine substitution at position 3 (Glu3 to Arg3) and a 13-amino acid N-terminal extension peptide derived from methionyl-porcine growth hormone. These modifications dramatically reduce its binding affinity for IGF-binding proteins (IGFBPs 1-6), which normally sequester over 98% of circulating native IGF-1, effectively increasing its bioactive free fraction and extending its functional half-life from approximately 12-15 minutes to 20-30 hours. Published research in the Journal of Biological Chemistry and Endocrinology has documented that IGF-1 LR3 activates the IGF-1 receptor (IGF-1R) with comparable potency to native IGF-1, triggering downstream PI3K/Akt/mTOR and Ras/MAPK signaling cascades that drive protein synthesis, cell proliferation, and anti-apoptotic responses. Preclinical studies have demonstrated that IGF-1 LR3 promotes both muscle hypertrophy (enlarged fibers) and hyperplasia (new fiber formation through satellite cell activation and myoblast fusion), a distinction from most anabolic agents that primarily drive hypertrophy alone. Research in agricultural science has documented significant increases in lean tissue accretion and feed efficiency when IGF-1 LR3 is used in livestock models, while cell biology research utilizes it extensively as a growth factor supplement in serum-free cell culture media. The extended bioactive window of IGF-1 LR3 makes it the most widely used IGF-1 variant in research applications requiring sustained IGF-1R activation without the confounding variable of IGFBP sequestration.
Handling & Storage
Published research protocols reference subcutaneous or intramuscular administration daily. Store at -20°C until reconstitution.
Published Research Protocols
Published research protocols reference 20-100mcg daily in 4-6 week cycles. Consult applicable literature for specific research applications.
Research Applications
Muscle Hyperplasia
Unlike most anabolic agents that drive only hypertrophy (larger existing fibers), IGF-1 LR3 has been demonstrated in preclinical research to promote genuine muscle hyperplasia — the formation of entirely new muscle fibers through satellite cell activation, proliferation, and fusion with existing myofibers. Published studies have documented increased muscle fiber number (not just size) following IGF-1 LR3 administration, mediated through the PI3K/Akt pathway's effects on myogenic regulatory factors MyoD and myogenin.
Initial effects within first month
Research Studies
Extended Half-Life
The Arg3 substitution and 13-amino acid N-terminal extension reduce IGFBP binding affinity by approximately 100-fold, liberating IGF-1 LR3 from the binding protein sequestration that normally limits native IGF-1's bioavailability to less than 2% of total circulating levels. Published pharmacokinetic research has documented a functional half-life of 20-30 hours compared to 12-15 minutes for native IGF-1, providing sustained IGF-1R activation that more effectively drives downstream anabolic signaling cascades over an extended time window.
Initial effects within first month
Research Studies
Nutrient Partitioning
IGF-1 LR3 activates PI3K/Akt signaling in skeletal muscle to enhance glucose transporter (GLUT4) translocation and amino acid uptake, while simultaneously promoting lipolysis in adipose tissue through suppression of lipogenic gene expression. Published research in agricultural and endocrine science has documented that this dual action effectively repartitions nutrients toward lean tissue accretion and away from fat storage, improving the ratio of muscle to adipose tissue gain during positive energy balance conditions.
Initial effects within first month
Frequently Asked Questions
How should I store this peptide?
Store IGF-1 LR3 lyophilized at -20°C for long-term preservation. Once reconstituted with bacteriostatic water or 0.1M acetic acid (the latter provides superior stability for IGF peptides), store at 2-8°C and use within 30 days. IGF-1 LR3 is more stable than native IGF-1 due to its modified structure, but the reconstituted solution should still be handled with care — avoid repeated freeze-thaw cycles and minimize room-temperature exposure.
What purity testing do you perform?
Every batch of IGF-1 LR3 undergoes testing at Janoshik Analytical Laboratory using reversed-phase HPLC for purity verification and mass spectrometry to confirm the correct molecular weight reflecting the Arg3 substitution and 13-amino acid N-terminal extension. The modified residues are specifically verified to ensure proper sequence identity and IGFBP resistance. Amino acid analysis confirms the complete 83-amino acid sequence. Our batches consistently achieve 99%+ purity.
What is the recommended reconstitution method?
Reconstitute IGF-1 LR3 with bacteriostatic water or 0.1M acetic acid (preferred for enhanced stability) by slowly injecting along the vial wall. Do not shake — IGF peptides can aggregate with mechanical stress. Allow 2-3 minutes for complete dissolution, gently swirling if needed. For cell culture applications, sterile-filtered 0.1M acetic acid is the recommended reconstitution solvent. For subcutaneous research applications, bacteriostatic water is standard.
Is this product for human use?
IGF-1 LR3 is sold for research purposes only and is not intended for human consumption. While native IGF-1 (mecasermin) has FDA approval for specific clinical indications, the LR3 modification is an investigational research variant. IGF-1 LR3 is widely used in cell biology research as a growth factor for serum-free cell culture systems and in preclinical studies investigating IGF-1R signaling. Always consult with a qualified healthcare professional before designing any research protocol.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Research Articles
Published research and educational content related to IGF-1LR3
Research12 min read
Growth Hormone Secretagogues: CJC-1295, Ipamorelin, GHRP-2 & GHRP-6 Research Overview
A comprehensive research overview of the major growth hormone secretagogues, including GHRH analogs and ghrelin receptor agonists, their mechanisms of action, selectivity profiles, and published preclinical and clinical findings.
Dr. James ParkResearch Analyst
Research12 min read
Semaglutide: A Comprehensive Research Guide to GLP-1 Receptor Agonists
An in-depth exploration of semaglutide research, covering its development history, GLP-1 receptor mechanism, pharmacokinetics, and how it compares to other incretin-based peptides in published studies.
Dr. James ParkResearch Analyst
Research11 min read
BPC-157 vs TB-500: Comparing Recovery Research Peptides
A detailed comparison of two of the most studied recovery peptides in preclinical research, examining their distinct mechanisms, published findings, and how investigators approach studying them individually and in combination.
Dr. Sarah ChenChief Science Officer
Research14 min read
Immune-Modulating Peptides: Thymosin Alpha-1, LL-37, and KPV Research
An overview of three key peptides being studied for their immune-modulating properties, covering innate and adaptive immune mechanisms, published research findings, and the current state of immunopeptide science.
Michael TorresContent Director
